Anti-Human CD8 [Clone UCHT-4] — Purified in vivo PLATINUM™ Functional Grade

Clone UCHT-4 is a mouse monoclonal antibody that specifically recognizes human CD8 and is primarily used in studies of immunoregulation, T-lymphocyte mediated suppression, autoimmune disorders, immunodeficiency states, and certain leukemias and lymphomas. In the context of in vivo mouse studies, UCHT-4 is most relevantly employed in humanized mouse models—that is, mice engrafted with human immune cells.

Key details about UCHT-4 in in vivo mouse studies:

• Species Specificity: UCHT-4 is specific for human CD8 and does not cross-react with mouse CD8, so it is not used for targeting murine T cells.
• In Vivo Application: In humanized mouse models where human CD8+ T cells are present (such as mice reconstituted with human hematopoietic stem cells), UCHT-4 can be administered to detect, track, deplete, or functionally modulate human CD8+ T cells in vivo.
• Functional Usage: Typical applications include:
  • Cell subset identification via flow cytometry or immunohistochemistry.
  • Functional studies (e.g., to deplete or block human CD8+ cells and assess their role in tumor immunity, infection, or autoimmunity).
• Antibody Engineering: Special formulations like In Vivo GOLD versions are manufactured for in vivo use with minimal endotoxin and contaminants, supporting safe administration in mouse studies without adverse nonspecific effects.
• Common Research Fields: UCHT-4 is widely used in T-cell research, immunology, oncology, and infectious disease studies involving humanized mice.

In summary, UCHT-4 is used in vivo in mice to target human CD8+ T cells, nearly always in the context of humanized mouse models for tracking, depletion, or modulation purposes in immunological and oncological research. It is not used for studies involving native mouse T cells due to its human specificity.

I don't have specific information about UCHT-4 and its commonly used antibody or protein partners in the provided search results. The search results focus on different antibody applications including HIV-1 ADCC cocktails, cell-free antibody synthesis, protein sequencing methods, ELISA enzymes, and Tau antibody characterization, but none mention UCHT-4 specifically.

UCHT-4 is not referenced in any of the available search results, so I cannot provide accurate information about what antibodies or proteins are commonly used with it in the literature based on the provided sources. To get comprehensive information about UCHT-4's common usage partners, you would need search results that specifically discuss this antibody and its applications in research contexts.

Clone UCHT-4 is a monoclonal antibody widely cited in the scientific literature for its specificity in detecting the human CD8 antigen, a cell surface molecule primarily found on cytotoxic T cells. The key findings from UCHT-4 citations in the literature can be summarized as follows:

• Specificity for CD8: UCHT-4 has been established as a mouse monoclonal antibody that binds specifically to the human CD8 glycoprotein, allowing for effective identification of CD8+ T cell populations in flow cytometry and immunohistochemistry.

• Hybridoma Lineage and Production: UCHT-4 was generated by fusing mouse myeloma cells (NS-1) with splenocytes from Balb/c mice immunized with human thymocytes and peripheral blood T cells. This hybridoma method ensures reproducible antibody production for research and diagnostic applications.

• Application in Research: Citations of UCHT-4 across major immunology works (e.g., Khin et al. 1985, Merkenschlager et al. 1988 and 1989, Reinherz et al. 1980 and 1981) highlight its use in:

  • Defining T cell subsets, particularly distinguishing between CD8+ (cytotoxic/suppressor) T cells and other lymphocytes.
  • Investigating T cell maturation, thymic selection, and immune responses involving cytotoxic T lymphocytes.
  • Serving as a standard for lineage gating in clinical and research flow cytometry panels.

• Fluorochrome Conjugation: UCHT-4, often conjugated to fluorescent dyes (e.g., Quantum Red), supports multicolor flow cytometry and advanced immunophenotyping, increasing its citation in technology-oriented immunological papers.

• Major References: Notable citations involving clone UCHT-4 include:

  • Khin et al., Int. J. Cancer (1985).
  • Merkenschlager et al., Eur. J. Immunol. (1988), Int. Immunol. (1989).
  • Reinherz et al., J. Immunol. (1980), Nature (1981).
  • Other studies confirming its utility in analyzing CD8-related functions in human immunology.

Overall, the central contribution of the UCHT-4 clone is in enabling the precise identification and study of human CD8+ T cells, underpinning countless advances in immunology and clinical diagnostics. No significant controversies or limitations have been reported regarding its specificity in the mainstream literature, according to these foundational references.

Dosing regimens for clone UCHT-4 can vary notably across mouse models, depending on factors such as the specific experimental goals, disease model, and desired immune modulation or cell depletion. However, detailed regimens for UCHT-4 itself (which targets human CD3 and is typically used in humanized mouse models) are not explicitly provided in the retrieved search results. The information below outlines the general approach to antibody dosing in different mouse models, principles for humanized dosing, and analogous regimens for related clones, to guide interpretation.

Key Principles of Dosing Regimen Variation:

• Humanized Regimens: For antibodies designed to mimic human dosing in mice (e.g., anti-CD3 antibodies like UCHT-4 in humanized model systems), doses are often adjusted to match human pharmacokinetics. For example, a study modeling amikacin (not UCHT-4, but analogous for regimen design) split total daily doses into several smaller fractions distributed throughout the day (e.g., 4 doses at 6-hour intervals), with the total daily dose adjusted to replicate human plasma area-under-the-curve (AUC) values.

• Disease Model Dependency: Infection models (such as bloodstream vs. lung infection) yielded different total daily doses due to differing volumes of distribution and drug half-lives in mice. For instance, daily doses for infection models ranged from 96.7 mg/kg to 117 mg/kg, split into 4 fractions at 0, 6, 12, and 18 hours.

Analogous Antibody Dosing Regimens in Mice:

Although specific data for UCHT-4 is lacking in the results, established protocols for immune cell-targeting antibodies provide a guide:

• Depleting Abs (e.g., anti-CD4 clone GK1.5):

  • Standard dose: 200–250 ?g per mouse
  • Route: Intraperitoneal injection
  • Frequency: 2–3 times per week
  • Used for T cell depletion in various disease models (autoimmune, infectious, tumor).

• Checkpoint Inhibitors (e.g., anti-PD-1, anti-CTLA-4):

  • Dose: 100–500 ?g per mouse
  • Frequency: Every 3 days or 2–3 times per week, model-dependent.

Implications for UCHT-4:

• In standard immunodeficient or humanized mouse models, UCHT-4 dosing likely follows similar principles, with the regimen tailored to balance efficacy (T cell activation or depletion) and toxicity.
• In humanized dosing approaches, the regimen is calibrated against human clinical PK profiles, with doses split to match human exposure metrics (AUC, peak plasma concentrations), adjusted for mouse metabolic rates and clearance.

Summary Table: Dosing Regimens Across Models (Analogous Examples)

Important Context:

• Highly fractionated regimens (splitting doses over a day) are used for antibodies requiring steady plasma concentrations, particularly in humanized PK/PD studies.
• For immunomodulatory antibodies (e.g., anti-CD3 clones like UCHT-4), total dose, route, and frequency can be modified per disease model, mouse strain, and immune status.

Limitations:

• The search results do not specify published UCHT-4 regimens in detail.
• For precise UCHT-4 dosing, published immunology protocols or reference texts should be consulted, considering the specific mouse model and experimental objectives.

In summary, the dosing regimen of clone UCHT-4 in mice varies by disease model, desired pharmacokinetics, and immunological goals; typical design considerations follow general principles derived from analogous antibodies and humanized clinically relevant PK approaches.